{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:29Z","timestamp":1788355349818,"version":"build-2803163510"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>\n                    Kidney transplant recipients often receive antibody induction. Previous studies of induction therapy were often limited by short follow-up and\/or absence of information about complications. After linking Organ Procurement and Transplantation Network data with Medicare claims, we compared outcomes between three induction therapies for kidney recipients. Using novel matching techniques developed on the basis of 15 clinical and demographic characteristics, we generated 1:1 pairs of alemtuzumab\u2013rabbit antithymocyte globulin (rATG) (5330 pairs) and basiliximab-rATG (9378 pairs) recipients. We used paired Cox regression to analyze the primary outcomes of death and death or allograft failure. Secondary outcomes included death or sepsis, death or lymphoma, death or melanoma, and healthcare resource utilization within 1 year. Compared with rATG recipients, alemtuzumab recipients had higher risk of death (hazard ratio [HR], 1.14; 95% confidence interval [95% CI], 1.03 to 1.26;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.01) and death or allograft failure (HR, 1.18; 95% CI, 1.09 to 1.28;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.001). Results for death as well as death or allograft failure were generally consistent among elderly and nonelderly subgroups and among pairs receiving oral prednisone. Compared with rATG recipients, basiliximab recipients had higher risk of death (HR, 1.08; 95% CI, 1.01 to 1.16;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.03) and death or lymphoma (HR, 1.12; 95% CI, 1.01 to 1.23;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.03), although these differences were not confirmed in subgroup analyses. One-year resource utilization was slightly lower among alemtuzumab recipients than among rATG recipients, but did not differ between basiliximab and rATG recipients. This observational evidence indicates that, compared with alemtuzumab and basiliximab, rATG associates with lower risk of adverse outcomes, including mortality.\n                  <\/jats:p>","DOI":"10.1681\/asn.2016070768","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T20:20:12Z","timestamp":1490041212000},"page":"2188-2200","source":"Crossref","is-referenced-by-count":51,"title":["Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation"],"prefix":"10.1681","volume":"28","author":[{"given":"Neel","family":"Koyawala","sequence":"first","affiliation":[{"name":"School of Arts and Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Silber","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"},{"name":"Department of Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Department of Statistics, Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Hill","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Reiter","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan A.","family":"Niknam","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Even-Shoshan","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy D.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Renal Electrolyte and Hypertension Division, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Sawinski","sequence":"additional","affiliation":[{"name":"Renal Electrolyte and Hypertension Division, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Nazarian","sequence":"additional","affiliation":[{"name":"Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Trofe-Clark","sequence":"additional","affiliation":[{"name":"Renal Electrolyte and Hypertension Division, Department of Medicine, and"},{"name":"Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Lim","sequence":"additional","affiliation":[{"name":"Renal Electrolyte and Hypertension Division, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse D.","family":"Schold","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Reese","sequence":"additional","affiliation":[{"name":"Renal Electrolyte and Hypertension Division, Department of Medicine, and"},{"name":"Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"B1-20230829","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"B5-20230829","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40472-015-0052-y","article-title":"The cost of transplant immunosuppressant therapy: Is this sustainable?","volume":"2","author":"James","year":"2015","journal-title":"Curr Transplant Rep"},{"key":"B6-20230829","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of united network for organ sharing registry data","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"B7-20230829","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl Int"},{"key":"B8-20230829","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijt.2014.06.001","article-title":"Outcomes of living donor renal transplant recipients with and without basiliximab induction: A long-term follow-up study","volume":"8","author":"Vardhan","year":"2014","journal-title":"Indian J Transplant"},{"key":"B9-20230829","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-128-10-199805150-00004","article-title":"The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data","volume":"128","author":"Szczech","year":"1998","journal-title":"Ann Intern Med"},{"key":"B10-20230829","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/ndt\/gfw086","article-title":"Efficacy and safety of antibody induction therapy in the current era of kidney transplantation","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B11-20230829","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"B12-20230829","doi-asserted-by":"crossref","first-page":"e111610","DOI":"10.1371\/journal.pone.0111610","article-title":"Mortality predictors in renal transplant recipients with severe sepsis and septic shock","volume":"9","author":"de Carvalho","year":"2014","journal-title":"PLoS One"},{"key":"B13-20230829","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1046\/j.1523-1755.2001.0590041539.x","article-title":"Exponentially increased risk of infectious death in older renal transplant recipients","volume":"59","author":"Meier-Kriesche","year":"2001","journal-title":"Kidney Int"},{"key":"B14-20230829","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B15-20230829","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"B16-20230829","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"B17-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/tri.12328","article-title":"Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation","volume":"27","author":"Yoon","year":"2014","journal-title":"Transpl Int"},{"key":"B18-20230829","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13063-015-0891-y","article-title":"Long-term safety and efficacy of antithymocyte globulin induction: Use of integrated national registry data to achieve ten-year follow-up of 10-10 study participants","volume":"16","author":"Lentine","year":"2015","journal-title":"Trials"},{"key":"B19-20230829","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000334092","article-title":"Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction","volume":"34","author":"Hurst","year":"2011","journal-title":"Am J Nephrol"},{"key":"B21-20230829","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0000000000000507","article-title":"Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States","volume":"99","author":"Schold","year":"2015","journal-title":"Transplantation"},{"key":"B22-20230829","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"B23-20230829","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"B24-20230829","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/j.1600-6143.2008.02373.x","article-title":"Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation","volume":"8","author":"Muthusamy","year":"2008","journal-title":"Am J Transplant"},{"key":"B25-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2146\/ajhp090636","article-title":"Induction immunosuppressive therapies in renal transplantation","volume":"68","author":"Gabardi","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"B26-20230829","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.transproceed.2010.04.019","article-title":"A review of the evidence for use of thymoglobulin induction in renal transplantation","volume":"42","author":"Gaber","year":"2010","journal-title":"Transplant Proc"},{"key":"B27-20230829","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.TP.0000134399.10352.E4","article-title":"The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function","volume":"78","author":"Knight","year":"2004","journal-title":"Transplantation"},{"key":"B28-20230829","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1198\/016214501753208573","article-title":"Balanced risk set matching","volume":"96","author":"Li","year":"2001","journal-title":"J Am Stat Assoc"},{"key":"B29-20230829","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/sim.2739","article-title":"The design versus the analysis of observational studies for causal effects: Parallels with the design of randomized trials","volume":"26","author":"Rubin","year":"2007","journal-title":"Stat Med"},{"key":"B30-20230829","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1198\/016214506000001059","article-title":"Minimum distance matched sampling with fine balance in an observational study of treatment for ovarian cancer","volume":"102","author":"Rosenbaum","year":"2007","journal-title":"J Am Stat Assoc"},{"key":"B31-20230829","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/01621459.2012.703874","article-title":"Using mixed integer programming for matching in an observational study of kidney failure after surgery","volume":"107","author":"Zubizarreta","year":"2012","journal-title":"J Am Stat Assoc"},{"key":"B32-20230829","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1541-0420.2011.01691.x","article-title":"Optimal matching with minimal deviation from fine balance in a study of obesity and surgical outcomes","volume":"68","author":"Yang","year":"2012","journal-title":"Biometrics"},{"key":"B33-20230829","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2215\/CJN.07540810","article-title":"Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States","volume":"6","author":"Gill","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34-20230829","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.TP.0000441089.39840.66","article-title":"Randomized trial of three induction antibodies in kidney transplantation: Long-term results","volume":"97","author":"Ciancio","year":"2014","journal-title":"Transplantation"},{"key":"B36-20230829","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"B37-20230829","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(14)61174-0","article-title":"Alemtuzumab induction therapy in kidney transplantation","volume":"384","author":"Kuypers","year":"2014","journal-title":"Lancet"},{"issue":"9955","key":"B38-20230829","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): A randomised trial","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"B39-20230829","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2215\/CJN.06950615","article-title":"Validating early post-transplant outcomes reported for recipients of deceased donor kidney transplants","volume":"11","author":"Potluri","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40-20230829","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"B41-20230829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ajt.12992","article-title":"Frailty and mortality in kidney transplant recipients","volume":"15","author":"McAdams-DeMarco","year":"2015","journal-title":"Am J Transplant"},{"key":"B42-20230829","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/j.ajkd.2015.05.015","article-title":"Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates","volume":"66","author":"Reese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B44-20230829","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O\u2019Donovan","year":"2005","journal-title":"Science"},{"key":"B46-20230829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-6143.2011.03826.x","article-title":"Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin","volume":"12","author":"Cortazar","year":"2012","journal-title":"Am J Transplant"},{"key":"B49-20230829","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.tp.0000251780.01031.81","article-title":"Early mortality rates in older kidney recipients with comorbid risk factors","volume":"83","author":"Kauffman","year":"2007","journal-title":"Transplantation"},{"key":"B50-20230829","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1532-5415.2007.01542.x","article-title":"Kidney transplantation in elderly people: The influence of recipient comorbidity and living kidney donors","volume":"56","author":"Wu","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"B51-20230829","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00007890-200003150-00037","article-title":"Increased immunosuppressive vulnerability in elderly renal transplant recipients","volume":"69","author":"Meier-Kriesche","year":"2000","journal-title":"Transplantation"},{"key":"B52-20230829","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/SLA.0b013e31825375ef","article-title":"Medical and financial risks associated with surgery in the elderly obese","volume":"256","author":"Silber","year":"2012","journal-title":"Ann Surg"},{"key":"B53-20230829","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CCM.0b013e3181b090d0","article-title":"Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs","volume":"38","author":"Halpern","year":"2010","journal-title":"Crit Care Med"},{"key":"B54-20230829","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1096-9098(199907)71:3<171::AID-JSO7>3.0.CO;2-8","article-title":"Pancreatic cancer: Total costs and utilization of health services","volume":"71","author":"Wilson","year":"1999","journal-title":"J Surg Oncol"},{"key":"B55-20230829","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00464-009-0728-4","article-title":"Opportunity cost in the evaluation of surgical innovations: A case study of laparoscopic versus open colectomy","volume":"24","author":"Chatterjee","year":"2010","journal-title":"Surg Endosc"},{"key":"B56-20230829","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.annemergmed.2004.08.029","article-title":"The cost of an emergency department visit and its relationship to emergency department volume","volume":"45","author":"Bamezai","year":"2005","journal-title":"Ann Emerg Med"},{"key":"B57-20230829","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/1475-6773.12156","article-title":"Template matching for auditing hospital cost and quality","volume":"49","author":"Silber","year":"2014","journal-title":"Health Serv Res"},{"key":"B58-20230829","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/1475-6773.12226","article-title":"A hospital-specific template for benchmarking its cost and quality","volume":"49","author":"Silber","year":"2014","journal-title":"Health Serv Res"},{"key":"B59-20230829","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamasurg.2015.4908","article-title":"Comparison of the value of nursing work environments in hospitals across different levels of patient risk","volume":"151","author":"Silber","year":"2016","journal-title":"JAMA Surg"},{"key":"B60-20230829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3111\/13696990701646577","article-title":"Choosing propensity score matching over regression adjustment for causal inference: when, why and how it makes sense","volume":"10","author":"Baser","year":"2007","journal-title":"J Med Econ"},{"key":"B61-20230829","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"B63-20230829","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/00007890-200109150-00018","article-title":"A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients","volume":"72","author":"Cole","year":"2001","journal-title":"Transplantation"},{"key":"B64-20230829","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.transproceed.2008.02.026","article-title":"Experience with alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression","volume":"40","author":"Baez","year":"2008","journal-title":"Transplant Proc"},{"key":"B65-20230829","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"B66-20230829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/biomet\/61.1.17","article-title":"Survival analyses in twin studies and matched pair experiments","volume":"61","author":"Holt","year":"1974","journal-title":"Biometrika"},{"key":"B67-20230829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2307\/2531957","article-title":"A paired prentice-wilcoxon test for censored paired data","volume":"43","author":"O\u2019Brien","year":"1987","journal-title":"Biometrics"},{"key":"B68-20230829","first-page":"54","article-title":"Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy","volume":"1","author":"Efron","year":"1986","journal-title":"Stat Sci"},{"key":"B69-20230829","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/biomet\/42.3-4.412","article-title":"A test for homogeneity of the marginal distributions in a two-way classification","volume":"42","author":"Stuart","year":"1955","journal-title":"Biometrika"},{"key":"B70-20230829","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1192\/bjp.116.535.651","article-title":"Comparing the classification of subjects by two independent judges","volume":"116","author":"Maxwell","year":"1970","journal-title":"Br J Psychiatry"},{"key":"B71-20230829","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/biomet\/66.1.163","article-title":"A note on exact robust confidence intervals for location","volume":"66","author":"Maritz","year":"1979","journal-title":"Biometrika"},{"key":"B72-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1353\/obs.2015.0000","article-title":"Two R packages for sensitivity analysis in observational studies","volume":"1","author":"Rosenbaum","year":"2015","journal-title":"Observ Stud"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201707000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:32:14Z","timestamp":1786131134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201707000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2016070768","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]}}}